Epitopea

PRESS RELEASE: Epitopea Strengthens Scientific Advisory Board We are pleased to announce the appointment of four world-renowned experts in cancer and immunotherapy to our Scientific Advisory Board:
 👤Prof. Nahum Sonenberg 👤 Dr. Bhardwaj Nina
 👤 Dr. Margaret Callahan 👤 Dr. Craig Slingluff Their collective expertise in immuno-oncology, translational research, and vaccine development will provide invaluable guidance as we advance our Cryptigen™-targeting RNA-based immunotherapies towards the clinic. 🔗 Learn more in our press release:
 English: https://lnkd.in/emPEs3CZ French: https://lnkd.in/eN34cjNE #Epitopea #CancerImmunotherapy #Innovation #Oncology #Biopharma #ImmunoOncology #ScientificAdvisoryBoard

Epitopea are hiring! We are looking for a strong Molecular Biologist to join our brilliant team here in Montreal. Check out our Job Post. https://lnkd.in/eh3Y6ykd

Honoured to be recognised! Epitopea has been selected as one of the finalists for Deal of the Year (<€500m) category at the LSX European Lifestars Awards - Celebrating Life Science Leaders, recognizing our strategic license and research collaboration with MSD. This partnership validates our proprietary CryptoMap™ platform to identify novel Cryptigen™ tumor-specific antigens (TSAs), accelerating the development of accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat cancers. Congratulations to our fellow finalists — Synaffix, Tubulis GmbH, aptaTargets, and Ascendis Pharma. We look forward to connecting and celebrating innovation in life sciences at the awards ceremony on 17 November 2025.

🚨 We're hiring a PostDoc!   Do you have a PhD in mass spectrometry data analysis, or bioinformatics and an interest in immuno-oncology?   Epitopea (Montreal) is looking for a PostDoctoral Fellow to join ongoing efforts in antigen discovery and immune profiling, with a focus on integrating:   ✅Mass-spec-based immunopeptidomics ✅Transcriptomics and proteogenomics   We’re particularly interested in candidates who: ✔️Have hands-on experience with LC-MS/MS data analysis ✔️Have a solid foundation in Python/R for data science   Previous exposure to tumor-specific antigen discovery and machine learning is a strong plus.   If this sounds like you (or someone in your network), please reach out directly or share your CV. Application closes August 20th. Happy to chat!   #postdoc #bioinformatics #proteomics #massspectrometry #immunopeptidomics #computationalbiology #immunooncology #antigendiscovery #Montreal #cancervaccines

We’re honoured to be shortlisted for the #BusinessWeeklyAwards2025! 🎉 This nomination reflects our pioneering work in cancer immunotherapy and the progress in developing our RNA-based immunotherapies supported by a successful pre-Series A financing, and a license & research collaboration with MSD. We’re excited to be in great company alongside other shortlisted leaders in the industry. Looking forward to celebrating the achievements of our peers and pushing the boundaries of science and innovation. 🔗 Learn more about Epitopea: https://lnkd.in/ekHRyBMs 📰 See the full shortlist here: https://lnkd.in/e3QRev8M #BusinessWeeklyAwards #LifeScienceInnovation #Epitopea #CancerImmunotherapy #CryptoMap #Immunotherapies #Innovation #CancerResearch #CambridgeTech #LifeScience #Biotech #Pharma #Cancer #Research #Science Business Weekly newspaper Tony Quested

Epitopea at Cambridge Healthtech Institute's 13th Annual Immuno-Oncology Summit Our CSO, Dr. Jon Moore, will be presenting a keynote on its CryptigenTM tumour selective antigens under the ‘Breakthroughs in Cell Therapy’ category, showcasing the identification of its novel targets for immunotherapies from the cryptic genome. 📍 Philadelphia, PA 🗓️ 11th August 2025, 10:25 AM 🗣️ "Cryptigen TSAs: Proteogenomic Identification of Novel Targets for Immunotherapies from the Cryptic Genome" We look forward to connecting with peers, partners, and collaborators to shape the future of immuno-oncology and help redefine cancer treatment. 🔗 Learn more about our science: https://lnkd.in/ekHRyBMs #ImmunoOncology #CancerImmunotherapy #Epitopea #CancerVaccines #TCRTherapies #SolidTumors #Biotech #Innovation #CryptoMap #ClinicalTrials

PRESS RELEASE: Epitopea Expands Clinical and Research Teams as It Accelerates to the Clinic We are excited to announce the formation of Epitopea’s dedicated clinical team and the expansion of our research team, marking a significant milestone in our progress toward advancing our CryptiVaxTM RNA-based immunotherapies into #clinicaltrials. Siri Torhaug, Head of Oncology Development, and Gertrud Koefoed Rasmussen, Head of Development Operations, are joining Epitopea’s Executive and clinical leadership teams, reporting to Dr. Klaus Edvardsen, our Chief Medical Officer. We’re also expanding our research capabilities with the addition of Dr. Theres Oakes as Director of Translational Sciences and Dr. Lisa Smith as Director of Research (UK), reporting to Dr Jon Moore. Both will work in close collaboration with our clinical team to seamlessly integrate research and clinical strategies. 🔗 Learn more about Epitopea’s progress: English: https://lnkd.in/e7HkS6jd French:  https://lnkd.in/epHynk6u #Epitopea #CancerImmunotherapy #ClinicalTrials #Innovation #Oncology #Biopharma #ImmunoOncology #ClinicalDevelopment

Epitopea at the International Neoantigen Summit 2025 🧬 We’re excited to share that our Chief Medical Officer, Dr. Klaus Edvardsen, will be contributing to two key sessions at the upcoming Neoantigen Summit in Amsterdam 🇳🇱 🗓️ Tuesday, 24 June – Pre-Conference Workshop C at 2:30 PM
 🧠 Workshop: How Personalised Should Neoantigen-Targeted Cell Therapies & Cancer Vaccines Be?
 Klaus will join fellow expert Robbert Spaapen, Associate Director of AstraZeneca 🗓️ Wednesday, 25 June at 12:00 PM – Main Conference Day 1
 🎤 Panel Discussion: Validating Immunogenicity of Neoantigens & Establishing a Consensus on Selecting Optimal Targets
 Here, Klaus will be accompanied by fellow panelists: Jingwei Sun, Vice President of R&D, Grit Biotechnology Sarah Maguire, CSO of AilseBio Reagan Jarvis, CEO of Anocca Katka Franke, Senior Director Cancer Antigen Discovery & Validation, CureVac 💬 Moderated by Vanesa Bol, GSK We look forward to these important conversations shaping the future of novel antigen-targeting strategies in immuno-oncology, and to connecting with our peers and collaborators in the field. 🔗 Learn about our CryptoMapTM platform and our Cryptigen™ tumor-specific antigens here: https://lnkd.in/ekHRyBMs #NeoantigenSummit #CancerImmunotherapy #Biotech #ImmunoOncology #Neoantigens #Innovation #CancerResearch #Epitopea Hanson Wade

Epitopea at #BIO2025! Our Chief Business Officer Steven Klein will be attending #BIO2025 – Biotechnology Innovation Organization from 16-19 June 2025 in Boston, MA 🇺🇸 Come talk to us about our recent license and research collaboration with MSD and our exciting Springer Nature Cancer Paper We look forward to exploring collaborations with industry leaders across the globe to advance the future of immunotherapy and cancer treatment. 🔗 Connect with us on BioPartnering: https://lnkd.in/dHqHkHhw 📢 Read our MSD collaboration press release here: https://lnkd.in/eCJXbbW9 📢 Read our Nature Cancer paper press release here: https://lnkd.in/ezmXMvuX #BIO2025 #CancerResearch #Immunotherapy #Biotech #Innovation #TCRTherapy #Oncology #Partnerships #TheWorldCantWait

Epitopea are hiring! We are looking for strong Immunologists to join our brilliant team here in Cambridge. Check out our Job Post. https://lnkd.in/eh3Y6ykd